NCTY
The paperwork finally got its green light
The9 Limited says its Singapore investee, Nanyang Biologics, just cleared a major regulatory hurdle: the SEC declared effective NYB’s Form F-4 registration statement. Translation? The legal paperwork for NYB’s planned Nasdaq debut is now much closer to the finish line, and the whole thing is tied to a previously announced $1.5 billion business combination.
Why investors should care
This isn’t the moment the champagne corks pop — it’s more like the point where the finish line finally comes into focus. The9 says it expects to own about 15% to 16% of the combined company after NYB lists, so any upside from the biotech story could feed back into The9’s balance sheet.
What matters here:
- NYB got SEC effectiveness for its Form F-4
- The listing is planned for Nasdaq under the reserved ticker NYB
- The9 expects to end up with a meaningful minority stake
The big-picture angle
For The9, this is one of those “wait, this is still happening?” updates that can matter a lot if the market decides it likes the story. A successful listing could put a cleaner price tag on the investment and maybe give The9 a more visible asset than a vague private-company footnote.
Big picture: it’s not money in the bank yet, but it is the kind of milestone that turns a PowerPoint dream into an actual market event.